Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.
Howell
Kobporn L
KL
Department of Medicinal Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA. kobporn_howell@merck.com
DeVita
Robert J
RJ
Garcia-Calvo
Margarita
M
Meurer
Roger D
RD
Lisnock
JeanMarie
J
Bull
Herbert G
HG
McMasters
Daniel R
DR
McCann
Margaret E
ME
Mills
Sander G
SG
D000818:Animals; D000924:Anticholesteremic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D001384:Azetidines; D000069438:Ezetimibe; D007093:Imidazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D007408:Intestinal Absorption / Q000187:drug effects; D026901:Membrane Transport Proteins / Q000187:drug effects*; D051379:Mice; D013141:Spiro Compounds / Q000138:chemical synthesis / Q000494:pharmacology; D013329:Structure-Activity Relationship
D000924:Anticholesteremic Agents; D001384:Azetidines; D007093:Imidazoles; D026901:Membrane Transport Proteins; C482445:Npc1l1 protein, mouse; D013141:Spiro Compounds; D000069438:Ezetimibe